According to our new market research study on “Middle East & Africa RNAi Therapeutics Market to 2027 - Regional Analysis and Forecast - by Molecule Type, Route of Administration, Application, and End User,” the Middle East & Africa RNAi therapeutics market is expected to reach US$ 29.02 million by 2027 from US$ 16.76 million in 2019, it is estimated to grow at a CAGR of 7.2% from 2020 to 2027. The report provides trends prevailing in the Middle East & Africa RNAi therapeutics market and the factors driving the market growth along with those hindering it.
In 2019, the small interfering RNAs (siRNA) segment accounted for higher share of the market. Growth of this segment is attributed to increasing preference for small interfering RNAs for drug development and growing number of research partnerships. The microRNA (miRNA) segment is expected to register higher CAGR in the RNAi therapeutics market during the forecast period.
The growth of the Middle East & Africa RNAi therapeutics market is mainly attributed to growing prevalence of chronic conditions and rising investments for development of RNAi therapeutics. Additionally, increasing awareness about RNAi therapies and their benefits are anticipated to boost the research and innovations of RNAi therapeutics in the region, which would eventually drive the market growth. However, the high cost of RNAi therapy development is the major factor hindering the market growth in Middle East & Africa.
Benitec Biopharma; Olix Pharmaceuticals, Inc; GlaxoSmithKline plc; Alnylam Pharmaceuticals, Inc; and Arrowhead Pharmaceuticals, Inc are among the leading companies operating in the Middle East & Africa RNAi therapeutics market.
The report segments the Middle East & Africa RNAi therapeutics market as follows:
Middle East & Africa RNAi Therapeutics Market - by Molecule Type
Middle East & Africa RNAi Therapeutics Market - by Route of Administration
Middle East & Africa RNAi Therapeutics Market - by Application
Middle East & Africa RNAi Therapeutics Market - by End User
Middle East & Africa RNAi Therapeutics Market - by Country
Reasons to Buy
In 2019, the small interfering RNAs (siRNA) segment accounted for higher share of the market. Growth of this segment is attributed to increasing preference for small interfering RNAs for drug development and growing number of research partnerships. The microRNA (miRNA) segment is expected to register higher CAGR in the RNAi therapeutics market during the forecast period.
The growth of the Middle East & Africa RNAi therapeutics market is mainly attributed to growing prevalence of chronic conditions and rising investments for development of RNAi therapeutics. Additionally, increasing awareness about RNAi therapies and their benefits are anticipated to boost the research and innovations of RNAi therapeutics in the region, which would eventually drive the market growth. However, the high cost of RNAi therapy development is the major factor hindering the market growth in Middle East & Africa.
Benitec Biopharma; Olix Pharmaceuticals, Inc; GlaxoSmithKline plc; Alnylam Pharmaceuticals, Inc; and Arrowhead Pharmaceuticals, Inc are among the leading companies operating in the Middle East & Africa RNAi therapeutics market.
The report segments the Middle East & Africa RNAi therapeutics market as follows:
Middle East & Africa RNAi Therapeutics Market - by Molecule Type
- Small Interfering RNAs (siRNA)
- MicroRNA (miRNA)
Middle East & Africa RNAi Therapeutics Market - by Route of Administration
- Pulmonary Delivery
- Intravenous Injections
- Intradermal Injections
- Intraperitoneal Injections
- Others
Middle East & Africa RNAi Therapeutics Market - by Application
- Oncology
- Cardiovascular
- Respiratory Disorders
- Renal Diseases
- Genetic Disorders
- Neurodegenerative Disorders
- Infectious Diseases
- Others
Middle East & Africa RNAi Therapeutics Market - by End User
- Research and Academic Laboratories
- Hospitals
- Diagnostic Laboratories
Middle East & Africa RNAi Therapeutics Market - by Country
- Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the MEA offshore pipeline market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the MEA offshore pipeline market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth MEA market trends and outlook coupled with the factors driving the offshore pipeline market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution
Table of Contents
1. Introduction
3. Research Methodology
4. Middle East & Africa RNAi Therapeutics Market - Market Landscape
5. Middle East & Africa RNAi Therapeutics Market - Key Market Dynamics
6. RNAi Therapeutics Market - Middle East & Africa Analysis
7. Middle East & Africa RNAi Therapeutics Market Analysis and Forecasts To 2027 - By Molecule Type
8. Middle East & Africa RNAi therapeutics Market Analysis and Forecasts To 2027 - By Application
9. Middle East & Africa RNAi therapeutics Market Analysis and Forecasts To 2027 - By Route of Administration
10. Middle East & Africa RNAi Therapeutics Market Analysis - By End-User
11. RNAi therapeutics Market Revenue and Forecasts To 2027 - Geographical Analysis
12. Impact of COVID-19 Pandemic on Middle East & Africa RNAi therapeutics Market
13. Company Profiles
14. Appendix
List of Tables
List of Figures
Companies Mentioned
A selection of companies mentioned in this report includes:
- Benitec Biopharma
- GlaxoSmithKline plc
- Olix Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals, Inc.